找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

123456
返回列表
打印 上一主題 下一主題

Titlebook: Hormone Related Cancer Mechanistic and Nanomedicines; Challenges and Prosp Mahfoozur Rahman,Waleed H Almalki,Khalid S Alharbi Book 2022 The

[復(fù)制鏈接]
樓主: CHORD
51#
發(fā)表于 2025-3-30 10:32:47 | 只看該作者
52#
發(fā)表于 2025-3-30 15:03:28 | 只看該作者
53#
發(fā)表于 2025-3-30 17:20:50 | 只看該作者
54#
發(fā)表于 2025-3-31 00:26:29 | 只看該作者
Book 2022g the imaging and drug delivery functions in one single nanoformulation, providing vital insights into the identification of tumour and predicting the efficacy of nanomedicine. For its unique properties, which include their small size and biocompatibility and ability to permeate the cellular membran
55#
發(fā)表于 2025-3-31 01:53:20 | 只看該作者
Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities,rteries and accumulate in plasma at high levels. In this chapter, we will look at the advancements of nanomedicine in all areas of pharmaceuticals. We will also discuss the challenges encountered during clinical testing and development of cancer medicines, as well as future opportunities.
56#
發(fā)表于 2025-3-31 06:25:12 | 只看該作者
Challenges and Opportunities in the Delivery of Oral Anticancer Therapeutics,ilability, pharmacokinetics, and biodistribution profiles. Here, we define the drug delivery challenges related to oral routes of administration and review innovative DDS, marketed or in development, that answer those challenges.
57#
發(fā)表于 2025-3-31 11:19:43 | 只看該作者
Nanocarriers-Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead,sis. Recently, significant attempts have been made to provide targeted-based nanocarriers to treat pancreatic cancer. This chapter tries to give information about the new possibilities of targeting pancreatic cancer via nanocarriers and challenges ahead.
123456
返回列表
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 14:15
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
贵港市| 会昌县| 奎屯市| 墨玉县| 鹤岗市| 阳谷县| 桂阳县| 康马县| 珠海市| 邵武市| 仁寿县| 和硕县| 洪洞县| 牟定县| 高邮市| 卓尼县| 项城市| 蛟河市| 元江| 南雄市| 泰来县| 禄劝| 托克逊县| 永泰县| 舞阳县| 台州市| 义乌市| 修文县| 平昌县| 洪雅县| 方城县| 合阳县| 罗田县| 陇南市| 项城市| 维西| 搜索| 秀山| 新兴县| 仲巴县| 石楼县|